Browse > Article
http://dx.doi.org/10.15207/JKCS.2022.13.01.161

N'-[(2-Hydroxy-1-naphthyl)methylene]arylhydrazides as Potent HIF-2α Inhibitors  

Lee, Hyosung (Department of Food & Pharmaceutical Science & Engineering, Seowon University)
Publication Information
Journal of the Korea Convergence Society / v.13, no.1, 2022 , pp. 161-166 More about this Journal
Abstract
HIF-2α is a transcription factor activated mainly in hypoxic condition known to play crucial roles in a wide variety of pathophysiological events including cancer, metabolic syndrome, arthritis etc. In this context, a number of N'-aryl isonicotinolyhydrazides, in which known pharmacophores are included, have been selected from commercial chemical library and tested for the inhibitory activities targeting HIF-2α in cultured HTB94 cell. HRE-luciferase and HIF-2α were introduced into the cell by transfection and adenoviri infection, respectively and the reporter gene assay discovered the potency of 2-hydroxy-1-naphthyl structure. Accordingly, the scaffold has been adjusted based on this structure and subjected to anti-HIF-2α activity test, identifying 2 compounds as HIF-2α inhibitors. The activities were confirmed by false positive test. This study has been performed via the convergence of biology and chemistry and the results may be useful for discovering novel inhibitors and HIF-2α biology studies, and contribute to the development of therapeutic agents.
Keywords
Convergence; $HIF-2{\alpha}$ inhibitor; HTB94 cell line; 2-Hydroxy-1-naphthyl; Isonicotinolyhydrazides;
Citations & Related Records
연도 인용수 순위
  • Reference
1 S. M. Siddiqui, A. Salahuddin & A. Azam. (2012). Synthesis, characterization and antiamoebic activity of some hydrazone and azole derivatives bearing pyridyl moiety as a promising heterocyclic scaffold. European Journal of Medicinal Chemistry, 49, 411-416.   DOI
2 G. Semenza. (2012). Hypoxia-inducible factors in physiology and medicine. Cell. 148(3), 399-408.   DOI
3 V. Wang et al. (2005). Differential gene upregulation by hypoxia-inducible factor -1α and hypoxia-inducible factor-2α in HEK293T cells. Cancer Research, 65(8), 3299-3306.   DOI
4 N. Albadari, S. Deng & W. Li. (2019). The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opinion on Drug Discovery, 14(7), 667-682.   DOI
5 C. M. Girgis et al. (2012). Novel links between HIFs, type 2 diabetes, and metabolic syndrome. Trends in Endocrinology & Metabolism, 23(8), 372-80.   DOI
6 F. Hajizadeh et al. (2019). Hypoxia inducible factors in the tumor microenvironment as therapeutictargets of cancer stem cells. Life Sciences, 237(116952), 1-13.   DOI
7 C. Corrado & S. Fontana. (2020). Hypoxia and HIF signaling: One axis with divergent effects. International Journal of Molecular Sciences, 21(16), 5611-5627.   DOI
8 S. Yang et al. (2010). Hypoxia-inducible factor2alpha is a catabolic regulator of osteoarthritic cartilage destruction. Nature Medicine, 16(6), 687-694.   DOI
9 C. J. Hu et al. (2003). Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Molecular and Cellular Biology., 23(24), 9361-9374.   DOI
10 B. Keith, R. S. Johnson & M. C. Simon. (2011). HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nature Review Cancer, 12(1), 9-22.   DOI
11 M. Ding et al. (2013). Y. I. Kim. (2017). Regulation of hypoxia-inducible factor 2-a is essential for integrity of the glomerular barrier. American Journal of Physiology-Renal Physiology, 304(1), F120-126.   DOI
12 J. E. Gunton. (2020). Hypoxia-inducible factors and diabetes. J Clin Invest, 130(10), 5063-5073.   DOI
13 D. Velmurugan, R. Pachaiappan & C Ramakrishnan. (2020). Recent Trends in Drug Design and Discovery. Currrent Topics in Medicinal Chemistry, 20(19), 1761-1770.   DOI
14 L. Yu et al. (2020). Oxygen therapy alleviates hepatic steatosis by inhibiting hypoxia-inducible factor-2α Journal of Endocrinology. 246(1), 57-67.   DOI
15 A. Didangelos et al. (2012). Novel role of ADAMTS-5 protein in proteoglycan turnover and lipoprotein retention in atherosclerosis. Journal of Biological Chemistry, 287(23), 19341-19345   DOI
16 M. P. Mattson. (2008). Hormesis defined. Ageing Research Review, 7(1), 1-7.   DOI
17 National Library of Medicine, National Center for Biotechnology Information (Bethesda, MD, USA). (Dec. 5, 2021) . N'-[(Z)-(2-oxonaphthalen-1-ylidene)methyl]pyridine-4-carbohydrazide. https://pubchem.ncbi.nlm.nih.gov/compound/4491.
18 National Library of Medicine, National Center for Biotechnology Information (Bethesda, MD, USA). (Dec. 15, 2021). 6-(hydroxymethyl)-N'-[(2-hydroxy-1-naphthyl)meth ylene]nicotinohydrazide. https://pubchem.ncbi.nlm.nih.gov/compound/135403085
19 M. Serocki et al. (2018). miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target. Angiogenesis, 21(2), 183-202.   DOI
20 S. Rollas & S. G. Kucukguzel. (2007). Biological activities of hydrazone derivatives. Molecules 12(8), 1910-39.   DOI